Clinical Trials

Study Title:
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma

For more information about the trial above please contact the study team: Medical University of South Carolina Principal Investigator, Albert Lockhart, at lockhara@musc.edu. Study Coordinator, Bria Sanders, at sandebri@musc.edu. Trial opened at the following institutions: Medical University of South Carolina